Reliable medication intake is a fundamental prerequisite for both therapeutic success and the validity of clinical trial outcomes. Deviations from prescribed regimens, including missed doses, incorrect timing or improper storage, can compromise efficacy assessments and introduce variability into study data. Around 50% of patients in clinical trials do not adhere fully to dosing requirements and approximately 40% discontinue correct intake after 150 days, resulting in prolonged and more costly studies. Even a 1% improvement in adherence in Phase III trials can reduce costs by an average of 335,700 US dollars.1 Digital adherence monitoring technologies provide objective, real-time data and offer a pathway to more robust, data-driven clinical development.